Literature DB >> 21365456

Lymphomatosis cerebri presenting as a rapidly progressive dementia with a high methylmalonic acid.

G Leschziner1, P Rudge, S Lucas, T Andrews.   

Abstract

We report a case of a patient with a rapidly progressive dementing illness and gait disturbance, in whom initial screening demonstrated a high methylmalonic acid level only, suggestive of a functional vitamin B(12) deficiency. Despite B(12) replacement therapy, he continued to decline. Further investigations demonstrated extensive signal change on magnetic resonance imaging involving grey and white matter within the corpus callosum, deep grey matter, brainstem and cerebellar peduncles, and patchy post-contrast enhancement. Laboratory testing revealed a raised erythrocyte sedimentation rate, raised anti-nuclear, intrinsic factor and lupus anticoagulant antibody titres, and a IgG kappa paraprotein. Cerebrospinal fluid was unremarkable. Bone marrow trephine biopsy showed monoclonal gammopathy of unknown significance. The patient initially responded to steroids, and underwent a brain biopsy, which was uninformative. However, 3 weeks following admission, he died due to an aspiration pneumonia. Autopsy findings were consistent with a diffuse primary central nervous system small cell B-cell lymphoma. This has been rarely reported in the medical literature, but our case exhibits typical clinical features, although patchy enhancement on imaging and the high methylmalonic acid have not been previously described. We hypothesise that his functional B(12) deficiency may have resulted from rapid cell turnover, perhaps in conjunction with the presence of intrinsic factor antibodies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21365456     DOI: 10.1007/s00415-011-5965-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man.

Authors:  Sonia Partap; Alexander M Spence
Journal:  J Neurooncol       Date:  2006-06-23       Impact factor: 4.130

Review 2.  MRI findings in lymphomatosis cerebri: description of a case and revision of the literature.

Authors:  Eytan Raz; Emanuele Tinelli; Manila Antonelli; Marco Canevelli; Marco Fiorelli; Luigi Bozzao; Vittorio Di Piero; Francesca Caramia
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

3.  Nonenhancing primary central nervous system lymphoma.

Authors:  S Terae; A Ogata
Journal:  Neuroradiology       Date:  1996-01       Impact factor: 2.804

4.  Lymphomatosis cerebri as a cause of white matter dementia.

Authors:  Karen E Rollins; B K Kleinschmidt-DeMasters; John R Corboy; Denise M Damek; Christopher M Filley
Journal:  Hum Pathol       Date:  2005-03       Impact factor: 3.466

5.  Rapidly progressive dementia caused by nonenhancing primary lymphoma of the central nervous system.

Authors:  B A Carlson
Journal:  AJNR Am J Neuroradiol       Date:  1996-10       Impact factor: 3.825

6.  Lymhomatosis cerebri--a rare cause of leukoencephalopathy.

Authors:  Lekha Pandit; Yasha Chickabasaviah; Ananthan Raghothaman; Sharik Mustafa; Arvind Vasudevan
Journal:  J Neurol Sci       Date:  2010-03-20       Impact factor: 3.181

7.  Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies.

Authors:  D G Savage; J Lindenbaum; S P Stabler; R H Allen
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

8.  Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review.

Authors:  Rachid Baz; Carlos Alemany; Ralph Green; Mohamad A Hussein
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

Review 9.  A case of 'lymphomatosis cerebri' diagnosed in an early phase and treated by whole brain radiation: case report and literature review.

Authors:  Ryuichi Kanai; Makoto Shibuya; Takashi Hata; Makoto Hori; Kenichi Hirabayashi; Tadashi Terada; Koji Fujii
Journal:  J Neurooncol       Date:  2007-07-05       Impact factor: 4.130

Review 10.  Primary central nervous system lymphomas.

Authors:  Julette F Batara; Stuart A Grossman
Journal:  Curr Opin Neurol       Date:  2003-12       Impact factor: 5.710

View more
  7 in total

1.  Neurocognitive features distinguishing primary central nervous system lymphoma from other possible causes of rapidly progressive dementia.

Authors:  Mariel B Deutsch; Mario F Mendez
Journal:  Cogn Behav Neurol       Date:  2015-03       Impact factor: 1.600

2.  Lymphomatosis cerebri presenting with orthostatic hypotension, anorexia, and paraparesis.

Authors:  Anjeni Keswani; Eileen Bigio; Sean Grimm
Journal:  J Neurooncol       Date:  2012-07-18       Impact factor: 4.130

Review 3.  Lymphomatosis cerebri: diagnostic challenges and review of the literature.

Authors:  Paul J Lee; Idanis Berrios; Carolina Ionete; Thomas Smith
Journal:  BMJ Case Rep       Date:  2016-11-24

Review 4.  Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature.

Authors:  Cristina Izquierdo; Roser Velasco; Noemí Vidal; Juan José Sánchez; Andreas A Argyriou; Sarah Besora; Francesc Graus; Jordi Bruna
Journal:  Neuro Oncol       Date:  2015-09-27       Impact factor: 12.300

5.  Lymphomatosis cerebri: a treatable cause of rapidly progressive dementia.

Authors:  Amit Samani; Indran Davagnanam; Oliver Charles Cockerell; Alan Ramsay; Rickie Patani; Jeremy Chataway
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-20       Impact factor: 10.154

6.  Primary diffuse large B-cell lymphoma of the CNS, with a "Lymphomatosis cerebri" pattern.

Authors:  Balamurugan Thirunavukkarasu; Kirti Gupta; Ritu Shree; Anuj Prabhakar; Aastha Takkar Kapila; Vivek Lal; Bishan Radotra
Journal:  Autops Case Rep       Date:  2021-04-20

7.  Neuroradiological features of lymphomatosis cerebri: A systematic review of the English literature with a new case report.

Authors:  Long Li; Jia-Hui Rong; Jie Feng
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.